Clinical Trial Update: Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of intermittent checkpoint inhibitor therapy for advanced urothelial carcinoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-02-25